Piramal Pharma Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Piramal's expertise across varied technologies makes them a partner of choice for innovators & generic companies worldwide.
One of their notable products is DROXIDOPA, with a corresponding US DMF Number 34258.
Remarkably, this DMF maintains an Active status since its submission on December 20, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 25, 2020, and payment made on December 31, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II